HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
HCW Biologics (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, announced that Wugen, a company in which it holds a minority stake, has secured a $115 million equity financing led by Fidelity Management & Research Company. The financing included participation from several prominent life sciences investors.
HCW Biologics' stake in Wugen originated from a 2020 Exclusive License Agreement, which has generated $16.2 million in revenues for HCW through license fees (paid in cash and Wugen stock) and clinical material sales. The funding will support Wugen's development of allogeneic, off-the-shelf CAR-T cell therapies.
HCW Biologics (NASDAQ: HCWB), un'azienda biopharmaceutica in fase clinica, ha annunciato che Wugen, in cui detiene una partecipazione minoritaria, ha ottenuto un finanziamento azionario di 115 milioni di dollari guidato da Fidelity Management & Research Company. Il finanziamento ha visto la partecipazione di diversi investitori importanti nel settore delle scienze della vita. La partecipazione di HCW Biologics in Wugen deriva da un Accordo di Licenza Esclusiva del 2020, che ha generato 16,2 milioni di dollari di entrate per HCW tramite commissioni di licenza (pagate in contanti e in azioni Wugen) e vendite di materiale clinico. Il fondo servirà a sostenere lo sviluppo da parte di Wugen di terapie CAR-T allogeneiche pronte all'uso.
HCW Biologics (NASDAQ: HCWB), empresa biofarmacéutica en fase clínica, anunció que Wugen, en la que posee una participación minoritaria, obtuvo una financiación accionarial de 115 millones de dólares liderada por Fidelity Management & Research Company. La financiación contó con la participación de varios inversores prominentes del sector de las ciencias de la vida. La participación de HCW Biologics en Wugen se origina en un Acuerdo de Licencia Exclusiva de 2020, que ha generado 16,2 millones de dólares en ingresos para HCW a través de tasas de licencia (pagadas en efectivo y en acciones de Wugen) y ventas de material clínico. Los fondos respaldarán el desarrollo por parte de Wugen de terapias CAR-T alogénicas, listas para usar.
HCW Biologics(NASDAQ: HCWB), 임상단계 바이오제약 기업은 지분의 일부를 보유한 Wugen이 Fidelity Management & Research Company가 주도한 1억 1,500만 달러 규모의 주식 자금 조달을 확보했다고 발표했습니다. 이번 자금 조달에는 다수의 주요 생명과학 투자자들의 참여가 포함되었습니다. HCW Biologics의 Wugen 지분은 2020년 독점 라이선스 계약에서 비롯되었으며, 이 계약으로 HCW는 라이선스 수수료(현금 및 Wugen 주식으로 지급) 및 임상 물질 매출을 통해 1,620만 달러의 수익을 얻었습니다. 자금은 Wugen의 동종 기성형(CAR-T) 세포 치료제 개발을 지원할 예정입니다.
HCW Biologics (NASDAQ : HCWB), entreprise biopharmaceutique en phase clinique, a annoncé que Wugen, dans lequel elle détient une participation minoritaire, a levé un financement en actions de 115 millions de dollars dirigé par Fidelity Management & Research Company. Le financement a recueilli la participation de plusieurs investisseurs de premier plan du secteur des sciences de la vie. La participation de HCW Biologics dans Wugen provient d'un accord de licence exclusive conclu en 2020, qui a généré 16,2 millions de dollars de revenus pour HCW via des frais de licence (paiés en espèces et en actions Wugen) et des ventes de matériel clinique. Le financement soutiendra le développement par Wugen de thérapies CAR-T allogéniques, prêtes à l'emploi.
HCW Biologics (NASDAQ: HCWB), ein klinisch beforschendes Biopharma-Unternehmen, gab bekannt, dass Wugen, an dem es eine Minderheitsbeteiligung hält, eine Eigenkapitalfinanzierung in Höhe von 115 Millionen USD unter der Leitung von Fidelity Management & Research Company gesichert hat. An der Finanzierung beteiligten sich mehrere prominente Investoren aus dem Bereich Life Sciences. Die Beteiligung von HCW Biologics an Wugen stammt aus einer exklusiven Lizenzvereinbarung von 2020, die HCW bislang Einnahmen in Höhe von 16,2 Millionen USD durch Lizenzgebühren (bar und in Wugen-Aktien) sowie durch den Verkauf klinischen Materials erzielt hat. Die Mittel sollen die Entwicklung von allogenen CAR-T-Zelltherapien bei Wugen unterstützen.
أعلنت HCW Biologics (بورصة ناسداك: HCWB)، وهي شركة أدوية حيوية في المرحلة السريرية، أن Wugen، الشركة التي تملك فيها حصة أقلية، قد حصلت على تمويل أسهم بقيمة 115 مليون دولار بقيادة Fidelity Management & Research Company. شاركت في التمويل عدة مستثمرين بارزين في مجال علوم الحياة. جاءت حصة HCW Biologics في Wugen من اتفاقية ترخيص حصرية أُبرمت في 2020، والتي ولّدت لـ HCW إيرادات قدرها 16.2 مليون دولار من خلال رسوم الترخيص (مدفوعة نقداً وبالأسهم الخاصة بـ Wugen) ومبيعات المواد السريرية. سيعزز التمويل تطوير Wugen لعلاجات CAR-T الخلوية allogeneic الجاهزة للاستخدام.
HCW Biologics（纳斯达克股票代码：HCWB），一家处于临床阶段的生物制药公司，宣布其持有少数股权的 Wugen 已完成1.15亿美元的股权融资，由 Fidelity Management & Research Company 领投。此次融资还获得了多位知名生命科学投资者的参与。HCW Biologics 在 Wugen 的股权源自2020年的独家许可协议，该协议通过许可费（以现金及 Wugen 股票支付）以及临床材料销售，为 HCW 产生了 1620 万美元 的收入。此次资金将支持 Wugen 开发同种异体、现成可用的 CAR-T 细胞治疗。
- Generated $16.2 million in revenues from Wugen license agreement
- Strategic minority stake in Wugen, which just raised $115 million
- Potential future value from Wugen's development of next-generation CAR-T therapies
- None.
Wugen closed a
Fidelity Management & Research Company
HCW Biologics holds a minority equity interest in Wugen
MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, congratulates Wugen, Inc. (“Wugen”) on its recently announced
HCW Biologics holds a minority equity interest in Wugen which it received as a license fee for the 2020 Wugen Exclusive License Agreement. Since inception, the Company recognized
Dr. Hing C. Wong, the Company’s Founder and CEO, stated, “As a shareholder of Wugen, we are excited to see a high-quality syndicate of institutional investors support Wugen’s continued development of their next generation of allogeneic, off-the-shelf CAR-T cell therapies.”
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/.
About Wugen:
Wugen, Inc., headquartered in St. Louis, Missouri, Wugen, is a pivotal-stage American-born biotechnology company advancing the next generation of off-the-shelf cell therapies. Its allogeneic therapies are derived from healthy donor cells and are engineered to deliver robust anti-tumor activity. With its proprietary CAR-T platform, Wugen is addressing critical unmet needs in hematologic malignancies. Its US-based manufacturing is optimized for scale, consistency, and rapid deployment, enabling the delivery of transformative therapies to patients with speed and precision. For more information, please visit https://wugen.com/.
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC.
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
FAQ
How much funding did Wugen raise in its latest equity financing round?
What is HCW Biologics' (NASDAQ: HCWB) relationship with Wugen?
How much revenue has HCW Biologics generated from its Wugen license agreement?
What is Wugen developing with the new funding?
Who were the major investors in Wugen's financing round?
